{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:21:35Z","timestamp":1773044495047,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T00:00:00Z","timestamp":1302739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Transmission of variant Creutzfeldt\u2010Jacob disease (vCJD) is a major concern in blood transfusion. The P\u2010Capt filter has been shown to remove around 4 log ID<jats:sub>50<\/jats:sub> prion infectivity from prion\u2010spiked human red blood cells (RBCs).<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Two independent, single\u2010center, randomized, open\u2010label studies were designed to analyze the safety of P\u2010Capt\u2013filtered RBCs. RBCs prepared from leukoreduced whole blood from 43 eligible subjects were randomly assigned to P\u2010Capt filtration and\/or storage in plasma or SAGM and stored for 28 or 42 days. Stored RBCs were analyzed for in vivo 24\u2010hour recovery, hemolysis, metabolic variables, blood group antigen expression, neoantigen formation, and safety after autologous infusion.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> Mean P\u2010Capt filtration times for leukoreduced RBCs were 41 (SAGM) to 51 (plasma) minutes. Thirteen of 14 subjects receiving P\u2010Capt\u2013filtered RBCs had 24\u2010hour RBC recoveries of 75% or more after 42\u2010day storage, with a mean hemolysis of less than 0.6%. No loss of RBC antigen expression or formation of neoantigens was observed. In both studies, RBCs had white blood cell counts of less than 1\u2003\u00d7\u200310<jats:sup>6<\/jats:sup>\/unit after leukofiltration. P\u2010Capt prion filtration provided an additional greater than 0.8 log leukoreduction. No serious or unexpected adverse events were observed after infusion of P\u2010Capt\u2013filtered full\u2010volume RBC units.<\/jats:p><jats:p><jats:bold>CONCLUSIONS:<\/jats:bold> P\u2010Capt\u2013filtered, stored RBCs demonstrated acceptable viability and no detectable neoantigen expression, immunogenic responses. or safety issues after infusion of a complete unit. The additional filtration time and modest reduction in RBC content are within acceptable levels for implementation in countries with transfusion transmission of vCJD.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2011.03133.x","type":"journal-article","created":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T13:45:13Z","timestamp":1302788713000},"page":"2228-2236","source":"Crossref","is-referenced-by-count":10,"title":["Infusion of P\u2010Capt prion\u2010filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of neoantigen formation"],"prefix":"10.1111","volume":"51","author":[{"given":"Jose A.","family":"Cancelas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeta","family":"Rugg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Gayle","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Nicole","family":"Worsham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan C.","family":"Pehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Banks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robertson D.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. John","family":"Judd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,14]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.23.13363"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91412-9"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.161.3839.388"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2767"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1580"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00833.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02181.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16820-7"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15487-1"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69897-8"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16812-8"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2008.01.028"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2294"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00865.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01330.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00918.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02500.x"},{"key":"e_1_2_8_20_2","first-page":"119","volume-title":"Evaluation of new red cell components for transfusion. Guidelines for the Blood Transfusion Services in the UK TSO (The Stationery Office)","author":"UK\u2010Blood\u2010Services","year":"2005"},{"key":"e_1_2_8_21_2","unstructured":"Council of Europe.Red cells in additive solution. Guide to the preparation use and quality assurance of blood components.2007;Chapter 12\u201014:113\u201028."},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2006.00694_28.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.2000.00230.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1980.tb07189.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1984.24284173339.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/188753a0"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2011.03133.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2011.03133.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T13:37:38Z","timestamp":1697290658000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2011.03133.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,14]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1537-2995.2011.03133.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2011.03133.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,14]]}}}